XBiotech Inc. Co-Chief Executive Officer Jan-Paul Simard filed a Form 4 on October 28, 2026, disclosing the grant of stock options to purchase 2,000,000 shares of common stock on October 26, 2026.

Key Highlights

  • Grant date: October 26, 2026, with options awarded under the Company's 2025 Equity Incentive Plan.
  • Exercise price: $1.85 per share, described as equal to the Nasdaq closing price on the grant date.
  • Shares covered: 2,000,000 shares of XBiotech Inc. common stock.
  • Expiration: Options expire ten years after the grant date, on October 26, 2036.
  • Vesting schedule: One-sixth vests on the 180th day following the grant date, with an additional one-sixth vesting every six months thereafter, subject to the Executive Employment Agreement.
  • Price paid: $0 for the derivative security at grant.
  • Resulting ownership: 2,000,000 derivative securities beneficially owned following the reported transaction, held directly.

XBiotech Co-CEO Jan-Paul Simard Receives 2,000,000 Stock Option Grant

According to the Form 4 filed with the SEC on October 28, 2026, Jan-Paul Simard, Co-Chief Executive Officer of XBiotech Inc. (NASDAQ:XBIT), received a grant of stock options on October 26, 2026. The filing reports the transaction under Table II, covering derivative securities, with a transaction code of "A" indicating an acquisition. The options carry an exercise price of $1.85 per share, which the filing states is "equal to the Nasdaq closing price on the Grant Date."

The options were granted under the Company's 2025 Equity Incentive Plan and cover 2,000,000 shares of XBiotech Inc. common stock. According to the filing, the options become exercisable beginning April 24, 2027, which corresponds to the 180th day following the grant date, when one-sixth of the options vest. An additional one-sixth is scheduled to vest every six months after that, "subject to the terms of the Executive Employment Agreement." The options expire on October 26, 2036, ten years from the grant date.

The filing indicates that Simard paid $0 for the options at the time of grant. Following the reported transaction, he beneficially owns 2,000,000 derivative securities directly. No transactions were reported in Table I covering non-derivative securities. The form was filed by one reporting person and is not marked as an amendment to a prior filing.

What Was Disclosed

XBiotech's Co-CEO Jan-Paul Simard disclosed receipt of a stock option grant for 2,000,000 shares at $1.85 per share under the 2025 Equity Incentive Plan, with a graduated vesting schedule and a ten-year expiration from the October 26, 2026 grant date.